The industry focused on living longer and healthier lives has changed significantly in recent years. Around 2015, this sector started with a lot of enthusiasm and investment, but many early companies disappeared again. That was because the challenges were great and the initial players had to make many mistakes to explore the terrain.
Nowadays, the longevity industry has become less straightforward and much more varied. Developing agents to slow down or even partially reverse the ageing process is a complicated and long-term process. This is now primarily happening through drug development, in which ageing is increasingly viewed as a medical condition that can be treated.
An important hurdle is that few drugs targeting ageing have yet been approved. Pharmaceutical companies are waiting for clear and widely accepted results, and for medicines that are also commercially successful. Only then will treating old age as something novel become normal within the medical world.
Although the sector is still currently struggling with funding and complex research, the approach to ageing will become increasingly integrated into healthcare. Ultimately, extending a healthy lifespan will become a permanent part of medicines and treatments.
This is important because it is increasingly possible to experience ageing healthily, with more years in good condition and fewer illnesses.
Source: Reason
